Sperimentazioni cliniche

Amiloidosi AL
  1. A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis
  2. Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
  3. High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease
  4. Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis
  5. Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
  6. A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
  7. A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
  8. Body Compositon in Systemic Amyloidosis (consulenza nutrizionale)
di prossima attivazione:
  1. A Multicentre Open label Phase II study of Daratumumab in AL Amyloidosis Patients not in VGPR or Better
  2. A Phase 2, Single Arm, Open Label, Efficacy and Safety Study of NEOD001 in Subjects with Light Chain (AL) Amyloidosis with Hepatic Involvement
  3. A randomized phase II/III trial of bortezomib-based therapy plus doxycycline vs. bortezomib-based chemotherapy plus standard supportive therapy in cardiac AL amyloidosis
  4. A phase III randomized study of doxycycline and tauroursodeoxycholic acid (Doxy/TUDCA) plus standard supportive therapy versus standard supportive therapy alone in cardiac amyloidosis caused by transthyretin

Amiloidosi AA
  1. Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis
Amiloidosi ATTR
  1. Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis
  2. Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis
  3. Efficacy and Safety of ISIS-TTRRx in Familial Amyloid Polyneuropathy